June 20, 2022

Edgewise Announces Positive 2-Month Interim Results from Open Label Study of EDG-5506 in Adults with Becker

Edgewise Therapeutics has announced 2-month interim results from the ongoing ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy. Results showed that EDG-5506 significantly lowered muscle damage biomarkers in adults with Becker,…

Learn More

April 15, 2022

Edgewise-Funded Natural History Trial Of Becker Muscular Dystrophy Now Enrolling

Edgewise Therapeutics has announced the start of an observational trial in participants with Becker muscular dystrophy to understand the disease progression as assessed by functional measures and imaging endpoints. The trial is expected to recruit…

Learn More

January 5, 2022

Edgewise Therapeutics Announces Positive Topline Results From EDG-5506 Phase 1b Trial in Adults With Becker

Edgewise Therapeutics today announced positive topline results from the Phase 1b clinical trial of EDG-5506 in Becker muscular dystrophy. EDG-5506 is an oral small molecule muscle stabilizer which seeks to protect the muscle from injuries…

Learn More

December 15, 2021

Edgewise Initiates ARCH Follow-On Open Label Becker Study; Will Report Phase 1b Topline Results on January 5

Edgewise Therapeutics has announced the initiation of the ARCH open label study of EDG-5506 in Becker muscular dystrophy, which will enroll participants from its Phase 1b clinical trial as well as new participants with Becker….

Learn More

October 28, 2021

Edgewise Therapeutics shares positive topline results from EDG-5506 Phase 1 Study and doses first Becker patients

Edgewise Therapeutics, Inc. announced today positive topline results from the Multiple Ascending Dose (MAD) portion of a first-in-human Phase 1 clinical trial assessing the safety and tolerability of escalating doses of EDG-5506, an orally administered…

Learn More

August 16, 2021

Edgewise Receives Fast Track Designation for EDG-5506 in Patients with Becker muscular dystrophy

Edgewise Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for…

Learn More